{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:52:43Z","timestamp":1787161963548,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1002\/hep.29837","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T13:08:48Z","timestamp":1518181728000},"page":"1861-1872","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":81,"title":["Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors"],"prefix":"10.1097","volume":"69","author":[{"given":"David","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla L.C.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Trebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palo","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Azim","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20241017","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-10-20241017","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-10-20241017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-10-20241017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV\u20101","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-10-20241017","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"H\u00e9zode","year":"2017","journal-title":"Liver Int"},{"key":"R7-10-20241017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All\u2010oral 12\u2010week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY\u20103 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"R8-10-20241017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3\u2014the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-10-20241017","first-page":"843","article-title":"Response guided interferon therapy for genotype 3 of chronic hepatitis C: compliance and outcome","volume":"31","author":"Sarwar","year":"2015","journal-title":"Pak J Med Sci"},{"key":"R10-10-20241017","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-10-20241017","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-10-20241017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"R13-10-20241017","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir plus velpatasvir combination therapy for treatment\u2010experienced patients with genotype 1 or 3 hepatitis C virus infection","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann Intern Med"},{"key":"R15-10-20241017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment\u2010induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R16-10-20241017","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R17-10-20241017","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J Hepatol"},{"key":"R18-10-20241017","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J Viral Hepat"},{"key":"R19-10-20241017","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/jmv.21850","article-title":"Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France","volume":"82","author":"Larsen","year":"2010","journal-title":"J Med Virol"},{"key":"R20-10-20241017","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"R21-10-20241017","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY\u20103+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"R22-10-20241017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016.","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"R24-10-20241017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"R25-10-20241017","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance\u2010associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"R26-10-20241017","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance\u2010associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"R27-10-20241017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance\u2010associated substitutions evaluated by sequencing\u2010based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"R28-10-20241017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"R29-10-20241017","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.02932-15","article-title":"Enhancement of the replication of HCV replicons of genotypes 1\u20104 by manipulation of CpG and UpA dinucleotide frequencies and use of cell lines expressing SECL14L2\u2014application for antiviral resistance testing","volume":"60","author":"Witteveldt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-10-20241017","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-10-20241017","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.12688\/f1000research.7111.1","article-title":"ve\u2010SEQ: robust, unbiased enrichment for streamlined detection and whole\u2010genome sequencing of HCV and other highly diverse pathogens","volume":"4","author":"Bonsall","year":"2015","journal-title":"F1000Res"},{"key":"R32-10-20241017","doi-asserted-by":"crossref","first-page":"e1002417","DOI":"10.1371\/journal.pcbi.1002417","article-title":"Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data","volume":"8","author":"Macalalad","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"R33-10-20241017","doi-asserted-by":"crossref","first-page":"e1002529","DOI":"10.1371\/journal.ppat.1002529","article-title":"Whole genome deep sequencing of HIV\u20101 reveals the impact of early minor variants upon immune recognition during acute infection","volume":"8","author":"Henn","year":"2012","journal-title":"PLoS Pathog"},{"key":"R34-10-20241017","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon\u2010alfa in patients with hepatitis C virus genotype 3 infection and treatment\u2010experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"R36-10-20241017","doi-asserted-by":"crossref","first-page":"e66129","DOI":"10.1371\/journal.pone.0066129","article-title":"A modified RNA\u2010seq approach for whole genome sequencing of RNA viruses from faecal and blood samples","volume":"8","author":"Batty","year":"2013","journal-title":"PLoS One"},{"key":"R37-10-20241017","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1016\/j.bmcl.2015.09.029","article-title":"Rethinking the old antiviral drug moroxydine: discovery of novel analogues as anti\u2010hepatitis C virus (HCV) agents","volume":"25","author":"Magri","year":"2015","journal-title":"Bioorganic Med Chem Lett"},{"key":"R38-10-20241017","doi-asserted-by":"crossref","first-page":"29487","DOI":"10.1038\/srep29487","article-title":"Exploration of acetanilide derivatives of 1\u2010(\u03c9\u2010phenoxyalkyl)uracils as novel inhibitors of hepatitis C virus replication","volume":"6","author":"Magri","year":"2016","journal-title":"Sci Rep"},{"key":"R39-10-20241017","doi-asserted-by":"crossref","first-page":"e0165339","DOI":"10.1371\/journal.pone.0165339","article-title":"Complex pattern of resistance\u2010associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure","volume":"11","author":"Itakura","year":"2016","journal-title":"PLoS One"},{"key":"R40-10-20241017","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre\u2010existing HCV variants resistant to direct\u2010acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"R41-10-20241017","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1128\/AAC.02776-15","article-title":"Comprehensive screening for naturally occurring hepatitis C virus resistance to direct\u2010acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6","volume":"60","author":"Pati\u00f1o\u2010Galindo","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-10-20241017","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R43-10-20241017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J Clin Virol"},{"key":"R44-10-20241017","doi-asserted-by":"crossref","first-page":"e0126764","DOI":"10.1371\/journal.pone.0126764","article-title":"Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia","volume":"10","author":"Wasitthankasem","year":"2015","journal-title":"PLoS One"},{"key":"R45-10-20241017","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","article-title":"Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries","volume":"67","author":"da Silva Filipe","year":"2017","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.29837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.29837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201905000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:16:06Z","timestamp":1729192566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201905000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29837","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}